Syros Pharmaceuticals Awaits Key SELECT-MDS-1 Trial Results for Tamibarotene in HR-MDS Treatment
- Syros Pharmaceuticals is preparing for pivotal SELECT-MDS-1 Phase 3 trial results for tamibarotene in mid-November.
- Positive trial results could lead to Syros filing its first New Drug Application for HR-MDS treatment.
- The company has $58.3 million in cash, projected to sustain operations into Q3 2025.
Syros Pharmaceuticals Prepares for Critical Trial Results in MDS Treatment
Syros Pharmaceuticals, a biopharmaceutical company dedicated to advancing therapies for hematologic malignancies, is on the brink of a pivotal moment with the SELECT-MDS-1 Phase 3 trial for tamibarotene. This trial specifically targets patients with higher-risk myelodysplastic syndrome (HR-MDS) exhibiting RARA gene overexpression, a patient demographic that has been historically underserved in terms of innovative treatment options. CEO Conley Chee expresses optimism regarding the trial’s topline results, which are expected to be announced in mid-November. Should these results be favorable, Syros plans to file its first New Drug Application (NDA), marking a significant milestone for the company and potentially transforming the treatment landscape for HR-MDS.
Tamibarotene has the potential to address a pressing need in the market, as it could provide a new therapeutic option for approximately 9,000 newly diagnosed HR-MDS patients in the U.S. annually. The urgency for new treatments is underscored by the fact that, beyond hypomethylating agents, there have been no new approvals for MDS therapies in over a decade. This context positions tamibarotene not just as a product, but as a beacon of hope for patients and healthcare providers seeking alternatives in an area long dominated by limited options. The company’s focus on this niche underscores its commitment to addressing critical medical needs, particularly in hematologic conditions.
In light of its recent financial report for Q3 2024, Syros faces challenges but remains focused on its strategic priorities. The company reports no revenue for the quarter, a decline from $3.8 million in Q3 2023, primarily due to the termination of a collaboration with Pfizer. However, there are signs of operational efficiency, as research and development expenses decrease from $28.3 million to $20.5 million year-over-year, alongside a reduction in general and administrative costs. The net loss of $6.4 million represents a significant improvement from the previous year’s loss of $40.1 million, reflecting the company's efforts to streamline operations while preparing for the upcoming trial results.
Amid these developments, Syros maintains a solid financial footing with $58.3 million in cash as of September 30, 2024, a decrease from $79.0 million in June. This funding is projected to sustain operations into the third quarter of 2025, allowing the company to focus on critical milestones without immediate financial pressure. A conference call is scheduled to delve deeper into these results and future plans, as Syros navigates this crucial phase in its development pipeline.